

Access status of Orphan Drugs (ODs) with trade names with orphan designation in force as of December 31, 2021

IN EU AND SPAIN

176 Products with trade name and orphan designation

OD with **market** authorization


With National Code in Spain (86%)

Financed by the **National Health System** (43%)

IN 2021



New **EMA market** authorizations



Spain

OD finaced by the **National Health System**

OD obtained the

National Code in

FINANCED IN SPAIN

% FINANCED

OD with market authorization and financed by the National Health System 2019 - 2021





AVERAGE WAITING TIME

OD with National Code and financed by the

National Health System 2019 - 2021

between National Code and entry into the National Health System

Months elapsed




Hematological or antithrombotic agent Metabolic

Oncological

Nervous System

OD FINANCED IN 2021 BY THERAPEUTIC AREA



price and financing resolution

7%

7%

PER NATIONAL CODE YEAR

16


Antiviral Ophthalmologic

Musculoskeletal System

Respiratory system

NO. OF UNFINANCED OD

55 orphan drugs are waiting for a favorable



ADVANCED THERAPIES

with orphan designation

Currently there are:

8 with National Code

in Europe

• 5 financed by the National Health System: O 2021: **2** advanced therapies

• 12 advanced therapies with market authorization

O Average waiting time for financing: **21 months**

APPROVALS AND FINANCING 2015-2021

2019 2020 2021

Market Authorization National Code National Health System



aelmhu.es

2015

2016

2017

The sources used in this report are always public and can be consulted at aelmhu.es

2018

